Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients.

Harrach S, Schmidt-Lauber C, Pap T, Pavenstädt H, Schlatter E, Schmidt E, Berdel WE, Schulze U, Edemir B, Jeromin S, Haferlach T, Ciarimboli G, Bertrand J.

Blood Cancer J. 2016 Sep 16;6:e470. doi: 10.1038/bcj.2016.79.

3.

Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.

Wang CP, Lehman DM, Lam YF, Kuhn JG, Mahalingam D, Weitman S, Lorenzo C, Downs JR, Stuart EA, Hernandez J, Thompson IM, Ramirez AG.

Cancer Prev Res (Phila). 2016 Oct;9(10):779-787.

PMID:
27026681
4.

Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).

Liang X, Chien HC, Yee SW, Giacomini MM, Chen EC, Piao M, Hao J, Twelves J, Lepist EI, Ray AS, Giacomini KM.

Mol Pharm. 2015 Dec 7;12(12):4301-10. doi: 10.1021/acs.molpharmaceut.5b00501.

5.

Role of solute carriers in response to anticancer drugs.

Li Q, Shu Y.

Mol Cell Ther. 2014 May 27;2:15. doi: 10.1186/2052-8426-2-15. Review.

6.

MDR1 transporter protects against paraquat-induced toxicity in human and mouse proximal tubule cells.

Wen X, Gibson CJ, Yang I, Buckley B, Goedken MJ, Richardson JR, Aleksunes LM.

Toxicol Sci. 2014 Oct;141(2):475-83. doi: 10.1093/toxsci/kfu141.

7.

An update on the pharmacogenomics of metformin: progress, problems and potential.

Todd JN, Florez JC.

Pharmacogenomics. 2014 Mar;15(4):529-39. doi: 10.2217/pgs.14.21. Review.

8.

Functional Characterization of ABCB4 Mutations Found in Low Phospholipid-Associated Cholelithiasis (LPAC).

Kim TH, Park HJ, Choi JH.

Korean J Physiol Pharmacol. 2013 Dec;17(6):525-30. doi: 10.4196/kjpp.2013.17.6.525.

9.

Membrane transporters as mediators of Cisplatin effects and side effects.

Ciarimboli G.

Scientifica (Cairo). 2012;2012:473829. doi: 10.6064/2012/473829. Review.

10.

Influences of organic cation transporter polymorphisms on the population pharmacokinetics of metformin in healthy subjects.

Yoon H, Cho HY, Yoo HD, Kim SM, Lee YB.

AAPS J. 2013 Apr;15(2):571-80. doi: 10.1208/s12248-013-9460-z.

11.

Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.

Wittwer MB, Zur AA, Khuri N, Kido Y, Kosaka A, Zhang X, Morrissey KM, Sali A, Huang Y, Giacomini KM.

J Med Chem. 2013 Feb 14;56(3):781-95. doi: 10.1021/jm301302s.

12.

Contribution of tumoral and host solute carriers to clinical drug response.

Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A.

Drug Resist Updat. 2012 Feb-Apr;15(1-2):5-20. doi: 10.1016/j.drup.2012.01.009. Review.

13.

Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin-induced lactic acidosis.

Toyama K, Yonezawa A, Masuda S, Osawa R, Hosokawa M, Fujimoto S, Inagaki N, Inui K, Katsura T.

Br J Pharmacol. 2012 Jun;166(3):1183-91. doi: 10.1111/j.1476-5381.2012.01853.x.

14.

Deficiency of multidrug and toxin extrusion 1 enhances renal accumulation of paraquat and deteriorates kidney injury in mice.

Li Q, Peng X, Yang H, Wang H, Shu Y.

Mol Pharm. 2011 Dec 5;8(6):2476-83. doi: 10.1021/mp200395f.

15.

A common 5'-UTR variant in MATE2-K is associated with poor response to metformin.

Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, Mefford JA, Hesselson SE, Schlessinger A, Jenkins G, Castro RA, Johns SJ, Stryke D, Sali A, Ferrin TE, Witte JS, Kwok PY, Roden DM, Wilke RA, McCarty CA, Davis RL, Giacomini KM.

Clin Pharmacol Ther. 2011 Nov;90(5):674-84. doi: 10.1038/clpt.2011.165.

16.

Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.

Müller F, König J, Glaeser H, Schmidt I, Zolk O, Fromm MF, Maas R.

Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8. doi: 10.1128/AAC.01835-10.

17.

Importance of the multidrug and toxin extrusion MATE/SLC47A family to pharmacokinetics, pharmacodynamics/toxicodynamics and pharmacogenomics.

Yonezawa A, Inui K.

Br J Pharmacol. 2011 Dec;164(7):1817-25. doi: 10.1111/j.1476-5381.2011.01394.x. Review.

18.

Functional characterization of liver enhancers that regulate drug-associated transporters.

Kim MJ, Skewes-Cox P, Fukushima H, Hesselson S, Yee SW, Ramsey LB, Nguyen L, Eshragh JL, Castro RA, Wen CC, Stryke D, Johns SJ, Ferrin TE, Kwok PY, Relling MV, Giacomini KM, Kroetz DL, Ahituv N.

Clin Pharmacol Ther. 2011 Apr;89(4):571-8. doi: 10.1038/clpt.2010.353.

19.

OCT2 and MATE1 provide bidirectional agmatine transport.

Winter TN, Elmquist WF, Fairbanks CA.

Mol Pharm. 2011 Feb 7;8(1):133-42. doi: 10.1021/mp100180a.

20.

Pharmacogenomic discovery using cell-based models.

Welsh M, Mangravite L, Medina MW, Tantisira K, Zhang W, Huang RS, McLeod H, Dolan ME.

Pharmacol Rev. 2009 Dec;61(4):413-29. doi: 10.1124/pr.109.001461. Review.

Supplemental Content

Support Center